The broad spectrum of substrates means GST activity has been implicated as a determinant of efficacy for many drugs [2,3], with isoenzyme, GST P1-1 most commonly associated with both innate and acquired drug resistance during cancer chemotherapy [1,4,5], including 5-fluorouracil- and cisplatin-resistant gastric cancers [6] and doxorubicin-resistant prostate cancer [7], because of overexpression in drug-resistant cell lines [8,9]. Here, GSTP1 is linked to cancer.